A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.
Jim Vondruska | Reuters
Wegovy, the heart failure symptoms in obese individuals”>popular weight loss drug from Novo Nordisk, significantly reduced symptoms of a common type of heart failure in patients with obesity, according to a late-stage clinical trial released Friday.
Wegovy helped alleviate symptoms like shortness of breath, fatigue, swelling in the legs and irregular heart beat. It also resulted in lower blood pressure and reductions in inflammation – two important markers of heart health.
The results add to Wegovy’s growing list of potential health benefits beyond shedding unwanted pounds. That could potentially lead to expanded use of the drug and increased coverage by insurers. The results also complement the groundbreaking trial data Novo Nordisk released earlier this month, which found that Wegovy slashed the risk of serious heart-related problems by 20%.
“We look forward to…
2023-08-25 13:02:18
Source from www.cnbc.com
